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Abstract 
All donor blood samples must be tested pre-transfusion to determine the donor blood type. Standard 
testing protocols also require that assays be performed for important blood borne pathogens such as 
hepatitis C, syphilis, hepatitis B and human immunodeficiency virus. We have developed a protein 
microarray which can type whole blood and detect antibodies to significant pathogens simultaneously 
from the same donor blood sample. The data shown demonstrate the ability of the array to accurately 
type blood samples whilst also detecting the presence of antibodies against both HIV and HCV. In 
conclusion we have successfully developed a platform capable of typing human whole blood samples, 
whilst at the same time testing for the presence of antibodies specific for HCV/HIV. The major 
benefits of this system are its amenability to expansion with additional assays, e.g. rhesus typing; 
syphilis and/or HBV detection; and also the adaptability of the assay for higher throughput analysis, 
currently 16 individual samples per slide, but readily expandable to a 96-well format. 
 
1. Introduction 
All donor blood samples must be blood typed prior to transfusion. This ensures the correct assignment 
of blood donations and avoids ‘transfusion reactions’ that are caused by agglutination or antibody-
dependent complement-mediated lysis of erythrocytes in the recipient when blood is transfused to an 
individual of a different blood group
[1,2]
. Current methods of blood testing include hemagglutination, 
enzyme-linked immunosorbent assays (ELISA) and nucleic acid testing; standard testing protocols 
also require that serological assays for important blood borne pathogens such as hepatitis C (HCV), 
syphilis, hepatitis B (HBV) and human immunodeficiency virus (HIV) be performed to ensure 
donation safety
[3,4,5,6]
 (and also see http://www.blood.co.uk/pdfdocs/tests_on.pdf). Although these 
tests are well characterised and widely used, they are performed separately and require that a number 
of centrifugation and/or washing steps be performed on the whole blood sample prior to analysis.  
Current screening for HIV in blood donations involves the detection of HIV-specific host antibodies 
in an Enzyme Immunoassay (EIA)/ELISA format. Samples with a non-reactive result from the 
EIA/ELISA are considered to be HIV negative, whilst those with a reactive result are re-tested in 
duplicate. If the re-test is also reactive, then the sample is tested further with an alternative method to 
ensure the correct diagnosis is given
[7]
. A similar principle is also applied to HCV testing
[6]
.  
An improved testing system for transfusion medicine would involve a robust test, capable of 
minimising sample and reagent use, whilst performing multiple tests on a single platform
[[8,9]
. 
Previous studies from our group have demonstrated the development and evaluation of a protein 
microarray platform capable of accurately phenotyping human erythrocytes
[10,11,12]
. However, the true 
value of a microarray platform in transfusion medicine is realised when multiple tests are combined 
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on the same array, since the cost of running a single microarray remains fairly stable regardless of 
how many individual components are incorporated into it
[8,9]
. Here we demonstrate that a protein 
microarray can be used to simultaneously type whole blood and perform serodiagnosis of pathogen 
infection. To achieve this, viral antigens were used for serodiagnosis of HIV and HCV, whereas 
antibodies were printed for the purpose of blood typing. 
 
2. Materials & Methods 
Selection of antigens for the serodiagnosis of HIV and HCV 
The suitability of a range of HIV/HCV antigens was initially tested by preparation of microarrays 
which were incubated with HIV antibody positive serum (Human HIV CAL+, Abbott, UK), HCV 
antibody positive serum (Human HCV CAL+, Abbott, UK) or negative control sera (Human HIV 
CAL- and HCV CAL-, Abbott, UK). A range of serum dilutions (1/20 – 1/1000) was tested and the 
optimum serum dilution was selected (1/30 in phosphate buffered saline (PBS) + 0.05% Tween 20 
(PBS-T) with 1 % bovine serum albumin (BSA)). The most promising antigens in terms of the 
greatest level of background corrected signal and the least amount of cross reactivity were chosen for 
use on the array and are listed in Table 1. 
 
Microarray preparation 
In order to allow multiple samples to be processed on the same slide, the Whatman Fast Frame™ 
system was utilised in conjunction with 16-well incubation chambers (Whatman Schleicher & 
Schuell, UK). This system allows up to four microarray slides to be held firmly together in a single 
frame. Microarrays were prepared by printing probes onto gold coated slides (25 x 75 x 1 mm, Ssens 
BV, NL)  using a MicroGrid II contact printer (Genomic Solutions, UK) with 200 µm solid pins. 
Multiple spotted replicates of the following capture, blood typing antibodies LA2, n = 3 (A-blood 
type specific, 0.82 mg/ml)) and LB2, n = 3 (B-blood type specific, 0.484 mg/ml) were printed onto 
the arrays. In addition, the range of HCV and HIV antigens (as selected above) were printed in 
triplicate (Table 1) along with PBS, n = 9 (pH 7.0) and PBS-T, n = 9 (pH 7.0) blank control spots and 
mouse IgG, n = 3 (0.31 mg/ml) as a secondary antibody positive control. Each slide was printed with 
16 separate arrays, allowing the simultaneous processing of up to 16 samples on the same slide. Each 
array consisted of a grid of 7x9 printed spots. Arrays were checked by microscopy after printing to 
ensure that probes were correctly printed and when not in use the arrays were stored under N2 at 4 °C. 
Prior to use arrays were submerged 10 times in PBS-T pH 7.0 + 1 % BSA before being placed in a 
fresh container of PBS pH 7.0 containing 1 % BSA for 1 hr at room temperature, with constant 
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agitation. Arrays were then submerged 10 times in a fresh container of PBS and centrifuged to 
dryness in an Eppendorf 5810R centrifuge at 1000 rpm for 1 min. 
 
Sample preparation 
Due to the difficulties involved in the safe handling of HIV/HCV infected blood samples in a research 
laboratory, and also in obtaining ethical approval for their use, a mock antibody-positive plasma 
sample was prepared utilising non-infected plasma diluted 1/30 in PBS-T (pH 7.0) containing 1% 
BSA. A range of monoclonal antibodies (MAbs) specific for HIV/HCV antigens was used to produce 
a mock antibody-positive plasma sample with a range of different antibody concentrations (6 x 10
-8
 
M, 6 x 10
-9
 M, 6 x 10
-10
 M, 2.4 x 10
-10
 M, 1.2 x 10
-10
 M, 6 x 10
-11
 M) see  Table 2. These samples were 
then used for testing the HIV/HCV assays. For blood typing analysis, erythrocytes of A and O blood 
types (Alba Biosciences, UK) were prepared by centrifuging for 5 minutes at 1,000 rpm prior to 
washing twice in ice cold PBS. In order to produce a mock whole blood sample the washed 
erythrocytes were re-suspended in plasma producing a final erythrocyte concentration equivalent to 
that of a normal human haematocrit level, i.e. 40%. For combined blood typing and serodiagnosis of 
pathogen infection a mock antibody-positive whole blood sample was created by adding erythrocytes 
(equivalent of a 40% haematocrit level) to a mock antibody-positive plasma sample. 
 
Sample incubation 
Samples (prepared as above) were contained on the array using 16-well incubation chambers 
(capacity = 120 µl) for 1 hr at room temperature with agitation. After incubation the samples were 
aspirated from the wells and the wells were washed 3 times with 100 µl PBS-T. The incubation 
chambers and Fast Frame supports were removed and the slides were then washed for 20 minutes in 
PBS-T and for 2 x 10 minutes in PBS. The slides were then centrifuged to dryness at 1000 rpm for 1 
min. Three separate arrays were used for each different condition. 
 
Blood typing data collection 
In order to assess blood-typing results, the microarray slides were scanned with a ScanArray 5000 
confocal microarray scanner (Packard Biochip Technologies) at 488 nm excitation and measuring 
emission at 520 nm to detect bound erythrocytes via their auto-fluorescence.  
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Serodiagnosis of pathogen infection data collection 
Following the collection of the blood typing data the microarray slides were placed back into the Fast 
Frame support along with fresh 16-well incubation chambers. In order to detect the bound anti-
HIV/HCV antibodies, 80 µl of Cy3 labelled anti-mouse IgG secondary antibody (1/1000 dilution, 
Sigma, UK) was added to each well and incubated, with agitation, for 1 hour at room temperature in 
the dark. A range of Cy3 labelled secondary antibodies was tested over a range of dilutions and a goat 
anti-mouse IgG (M412, Sigma, UK) was found to give the optimum result at a dilution of 1/1000 in 
PBS-T + 1 % BSA. The secondary antibody was then aspirated and each well rinsed with 3 x 100 µl 
PBS-T. The Fast Frame supports and incubation chambers were carefully removed and the slides were 
washed for 20 minutes in PBS-T and 2 x 10 minutes in PBS. The slides were centrifuged to dryness 
(1,000 rpm for 1 min) and scanned using a ScanArray 5000 confocal microarray scanner (Packard 
Biochip Technologies) with excitation at 550 nm and measuring emission at 570 nm to detect the Cy3 
fluorescence signal. 
 
Data processing and analysis 
Slides were scanned as described above; for each array five separate scans were taken using a 
constant photomultiplier tube (PMT) setting and incrementally increasing laser power settings. 
Microarray images were analysed with Quantarray software (Perkin Elmer, USA) using the fixed 
circle method and spot-specific background was corrected by subtracting measured spot background 
from spot signal. From the five scans of each array, the optimal scan in terms of linear range was 
selected on the basis of comparative scatterplot analysis
[13]
.  
 
Blood typing 
We have previously described the development and evaluation of a protein-based microarray capable 
of successfully phenotyping human whole blood samples
[12]
. We developed a novel diagnostic 
algorithm which allowed the accurate determination of the ABO blood type of randomly assigned 
blood samples. Herein we utilised the same algorithm to phenotype erythrocytes incubated on the 
microarrays for combined testing. The algorithm utilises Receiver Operator Characteristic (ROC) 
curve analysis to produce a series of threshold values within which a sample can be assigned a 
particular blood phenotype. The threshold values are based upon an index score (ratio) of the A and B 
blood type antibody responses (LA2/LB2) and are defined in Table 3.  
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The background corrected signals were used to determine the index scores, with background noise 
being calculated from the median signal of the 18 PBS/PBS-T control spots printed on each array. 
Representative mean signal for a probe xi (probe x on array i) was calculated as the median 
fluorescence across all replicates of a probe on an array (LA2, n = 3, LB2, n = 3). The relative signal 
(index score) between the anti-A (LA2) and anti-B (LB2) probes was then defined as the ratio 
LA2i/LB2i. The threshold values defined in Table 3 were then applied to the blood typing data 
collected in this study to determine whether the combined pathogen and blood phenotyping array was 
capable of accurately determining the blood type of the erythrocytes contained in the mock blood 
samples. A sample of blood type A would be expected to give a strong response to the type A specific 
antibody and no response to the type B specific antibody, whilst a sample of blood type O would be 
expected to show no response to both of these probes. The reason for this is that type O erythrocytes 
carry neither, type A or B antigens as such a double negative response would be the expected outcome 
for this blood type.  
 
Serodiagnosis of pathogen infection analysis 
The median signals obtained from the triplicate printed HIV/HCV antigen spots were background 
corrected by dividing them by the median fluorescence signal from the 18 PBS/PBS-T printed control 
spots. The mean signal/background value for each sample was used to calculate the relative signal 
value for each antigen by dividing it by the mean signal/background value obtained with a plasma 
only reference sample. The mean relative signal values for each antigen were then used to assess the 
performance of each of the pathogen antigens across a range of plasma and blood samples. 
 
3. Results 
Antigen cross-reactivity analysis 
To ensure specificity, the individual HIV/HCV antigens (See Table 1) were tested for cross-reactivity 
with HIV/HCV antibody positive sera. In this experiment a range of secondary antibody dilutions was 
also tested (1/400, 1/1000, 1/2000). Encouragingly, the data demonstrated very little cross reactivity 
between the HCV antigens and the HIV antibody positive serum with relative signal values of 
between 0.28 – 1.16, whilst the HIV antigens showed far higher relative signal values ranging from 
1.15 - 6.27 (at the optimum secondary antibody dilution of 1/1000) (See Supplementary Figure 1). In 
addition the HIV antigens showed very little cross reactivity with the HCV antibody positive serum 
(relative signal value range = 0.65 – 1.74) whilst the HCV antigens showed higher relative signal 
values of 2.53 – 8.61 (See Supplementary Figure 1). 
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Performance of mock antibody-positive plasma against selected HIV/HCV antigens 
The best performing antigens from initial trials, Virostat HCV NS3 Fusion, Fitzgerald HCV NS3, 
Virogen HIV-2 env gp36 and RDI HIV-2 env gp36 were tested using a range of antibody 
concentrations. Figure 1 shows a dose response curve for the HIV/HCV mock antibody-positive 
plasma against the four best performing HIV/HCV antigens. In order to aid visualisation of this data it 
was plotted on a log scale of the monoclonal antibody concentrations (calculated based upon the 
molecular mass of IgG as 1.5 x 10
6
). As can be seen, the best sensitivity for detection of all four 
antibodies in the mock antibody-positive plasma falls between 6 x 10
-10
 M and 2.4 x 10
-10
 M where 
the dose response curve is at its steepest point within the linear range. We chose three concentrations 
that spanned the linear phase for the response to these antigens (6 x 10
-10
 M, 4 x 10
-10
 M and 2.4 x 10
-
10
 M) for use in further evaluation of the array for combined testing. 
 
Blood typing 
Human erythrocytes of either A or O blood type were added to the mock antibody-positive plasma to 
create mock antibody-positive ‘whole blood’ samples. These samples were blood typed using the 
protein microarray platform (Fig. 2) and the data analysed against the blood typing thresholds defined 
in a previous study by our group
[12]
. 
The protein microarray method was able to successfully discriminate between the A and O blood type 
erythrocytes used in the mock antibody-positive human ‘whole blood’ samples (Fig. 2). A relative 
signal value of between 5-7 was seen with the A blood type whilst a signal of approximately 1 was 
seen with the O blood type for the LA2 antibody (Type A specific). In addition, the LB2 (Type B 
specific) antibody showed relative signals of approximately 1 for both the A and O blood types. The 
relative signal values were also very low (less than 2 for all but one of the antigens) for the HIV/HCV 
antigens, indicating that there was very little cross reactivity between the erythrocytes and the 
pathogen specific antigens. However it should be noted that the Virostat HCV core antigen showed 
some cross reactivity with the type O erythrocyte sample (Fig. 3), as such this antigen was removed 
from the final analysis. The results from the blood-typing analysis were analysed using the previously 
defined blood typing thresholds described in Table 3, the results showed that the protein microarray 
method successfully typed the A (Index Score = 3.63 – 3.93) and O (Index Score = 1.31 – 1.56) blood 
type samples both in the presence and absence of the HIV/HCV specific monoclonal antibodies. 
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Serodiagnosis of pathogen infection 
Relative signal responses to the HIV/HCV antigens were assessed with the mock antibody-positive 
human ‘whole blood’ samples. During the blood typing analysis the Virostat HCV core antigen 
showed cross-reactivity with the O erythrocyte sample, and was removed from the pathogen detection 
analysis, thus leaving two HCV antigens (Virostat HCV NS3 Fusion and RDI HCV NS4) and four 
HIV antigens (NIBSC HIV-1 gp41, NIBSC HIV-1 p24 His, RDI HIV-2 env gp36 and Virogen HIV-2 
env gp36). Positive control spots of mouse IgG (reacts with the anti-mouse IgG secondary antibody) 
were spotted onto the arrays and in all cases these spots, as expected, gave relative signal values close 
to one, indicating similar responses for plasma only and mock antibody-positive ‘whole blood’ 
samples.  
With the monoclonal antibodies at a concentration of 6 x10
-10
 M, the most promising HCV antigens 
were the RDI HCV NS4 antigen (relative signal values of 42 (O type blood) and 40 (A type blood), 
indicating that the response with the mock antibody-positive plasma was approximately 40 times 
greater than that with the plasma sample) and Virostat HCV NS3 antigen (relative signal values of 8 
(O type blood) and 7 (A type blood)) (Fig. 3). The most promising HIV antigens were the RDI HIV-2 
env gp36 antigen (relative signal values of 9 (O type blood) and 7 (A type blood)) and Virogen HIV-2 
env gp36 (relative signal values of 4 (O type blood) and 3 (A type blood)). The two HIV-1 antigens 
from NIBSC (HIV-1 gp41 and HIV-1 p24 His) did not perform as well with relative signal values 
between 0.42 and 1.36 (Data not shown).  
It was noted that the relative signal responses between the A and O blood type samples and the 
sample with no erythrocytes correlated very well, indicating the robustness of the assay to differences 
in blood composition and different ABO blood types. By far the best performing antigens were the 
RDI HCV NS4 and the RDI HIV-2 env gp36. The best sensitivity for monoclonal antibody detection 
used in the mock antibody-positive plasma differed slightly for the best performing antigens but 
generally they fell in the sub-nanomolar range between 6 x 10
-10
 and 2.4 x10
-10
 M as predicted by the 
dose response curve (Fig. 1). In addition all antibodies were detected at 6 x 10
-10
 M regardless of the 
presence of erythrocytes (Fig. 3). 
 
4. Discussion 
Previous results from our group have demonstrated the feasibility of using a protein based microarray 
platform to type donor blood samples with minimal sample treatment
[10,11,12]
. This study has built 
further on these results by demonstrating that the technique can be successfully combined with the 
serodiagnosis of multiple pathogen infections on the same microarray platform. While other 
publications have shown impressive multiplexed virus detection,
[14, 15]
 we believe that this is the first 
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example of integration of such tests with blood typing and is a critical step in the development of 
integrated pre-transfusion tests. 
In order to make the assay more amenable to multiple probe testing and to allow the optimisation 
steps required of a multiple ELISA type assay we miniaturised the array footprint to allow the printing 
of multiple arrays per slide, currently 16. This layout enabled us to make use of 16 well incubation 
chambers and Fast Frame™ format (Whatman, Schleicher & Schuell, UK) meaning that we could run 
multiple samples (such as different antibody concentrations) on the same slide with no leakage 
between samples. This allowed us to minimise the variation associated with sample handling and 
processing and also allowed accurate comparisons to be made between different conditions. In 
previous studies we have demonstrated greater signal-noise responses when blood typing was 
performed on gold coated slides
[11]
. We acknowledge that gold is not a well-recognised surface for 
performing immunoassays and while we also printed and analysed on epoxy silane coated glass slides 
(data not shown) we found that the best fluorescent signals were observed on the gold surface and as 
such we have only shown these results here. 
We utilised HIV and HCV antibody positive sera to determine the level of cross reactivity between 
the selected HIV/HCV antigens. The data showed very little cross reactivity between the HIV positive 
sera and the selected HCV antigens and vice versa, indicating good specificity with the antigens 
selected. This result showed that it was possible to use multiple antigens to simultaneously detect host 
antibodies specific for multiple pathogens in serum with very little cross reactivity, strong relative 
signals and minimal sample fractionation and purification.  
While we assayed for antigen cross reactivity using positive sera, the limited availability of this 
resource, meant that it was more practical to use mock antibody-positive plasma for dose response 
and further experiments. The HIV/HCV mock antibody-positive plasma proved to be an excellent 
model analyte and the array was able to detect the presence of HIV/HCV specific monoclonal 
antibodies in the sample with strong responses being observed with all four antigens. The best 
sensitivity for monoclonal antibody detection in the mock antibody-positive plasma was chosen as the 
region of the dose-response curve with the highest gradient (http://goldbook.iupac.org/S05606.html).  
Mock antibody-positive human ‘whole blood’ samples were simultaneously blood typed and analysed 
for the presence of HIV/HCV specific antibodies using the microarray platform. The mean index 
scores for the mock antibody-positive human ‘whole blood’ samples were calculated and the 
threshold values defined in Table 3 were then used to assign the samples with a particular ABO blood 
type. The combined use of the protein microarray and the threshold values allowed us to accurately 
predict the blood types for the A and O type mock antibody-positive human ‘whole blood’ samples. In 
addition, by testing in the presence and absence of the monoclonal antibodies we were able to 
conclude that the mock antibody-positive plasma had no detrimental affect on the array’s ability to 
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accurately predict the blood type of the erythrocytes. In order to successfully phenotype type O 
erythrocytes our microarray test depends on the presence of two negative responses (LA2 and LB2), 
however one way of improving the assay and ensuring that type O samples are correctly predicted 
would be to utilise a positive control for type O blood such as an additional probe for H-antigen, 
which is the common precursor of the A and B antigens
[16]
. 
Once the slides had been scanned for ABO blood typing the secondary (goat anti-mouse) antibody 
was added to each well to measure the responses to the pathogen specific antigens. Slides were then 
scanned a second time (for Cy3) and the relative signal responses to the HIV/HCV antigens were 
determined. The detection of the antibodies by printed antigens in the mock antibody-positive plasma 
is measured by the relative signal response, calculated by dividing the signal/background value for 
each antigen by the signal/background value for that antigen in the plasma only sample. The results of 
the pathogen detection demonstrated clear positive responses for two of the HCV and two of the HIV 
antigens. The data showed that for the monoclonal antibodies the best sensitivity was in the region of 
6 x 10
-10
 M. By far the most promising HCV antigen was the RDI HCV NS4 which showed a 40-fold 
increase in relative signal responses for the mock antibody-positive plasma compared to the plasma 
only control. The response for the Virostat HCV NS3 fusion antigen was also easily detectable with 
relative signal values of up to 10. The HIV antigens also showed very encouraging results, with the 
most promising antigen being the RDI HIV-2 gp36 with relative signal responses up to 13. 
This study has described the development of a combined assay for simultaneous blood typing and 
serodiagnosis of pathogen infection on a single protein microarray platform. The assay as described 
utilises an anti-mouse secondary antibody (Cy3 labelled) to detect the binding of mouse anti-
HIV/HCV monoclonal antibodies from the mock antibody-positive plasma. As the blood typing 
antibodies used (LA2 and LB2) are mouse antibodies, the anti-mouse secondary antibody can cross 
react with these probes giving false signals. In the development of the assay we overcame this 
problem by first incubating the mock antibody-positive human ‘whole blood’ samples on to the arrays 
and scanning for the erythrocyte specific signal and then adding the secondary antibody and scanning 
for the Cy3 pathogen specific signal. In a real diagnostic assay, the antibodies detected would be 
human anti-HIV/HCV, therefore the secondary antibody used could also be human specific and would 
not then be expected to react with the LA2 and LB2 antibodies printed on the array. This would allow 
us to scan the slide on a single occasion, obtaining both the erythrocyte auto-fluorescence signal and 
Cy3 pathogen-specific signal without any pre-processing or further incubations between scans, giving 
a faster result and a less complicated assay. 
Further improvements to the assay could be gained by printing additional features such as antibodies 
specific for HIV/HCV antigens thus allowing the detection of pathogen specific antigens in the 
blood
[8]
.
 
This would add further power to the assay by allowing the simultaneous detection of host 
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antibodies and pathogen specific antigens. In addition, further HIV/HCV antigens could be added to 
the assay to provide a more in depth coverage of viral strains. Our group have also investigated the 
use of this assay to detect other blood borne pathogens and in particular further tests for syphilis and 
HBV have shown great promise. 
One major advantage of this system is the fact that we can simultaneously process up to 16 samples 
on a single microarray slide. This helps to reduce the level of variation due to handling/operator issues 
as the samples are processed and scanned together and it also helps to reduce the overall costs of the 
assay as up to 16 test arrays can be printed onto a single slide. A further development to this system 
would be to move to a 96-well plate format, whereby single arrays are printed into individual wells of 
a 96-well plate. This would allow 96 individual samples to be processed simultaneously, greatly 
reducing the overall cost per assay. This would also bring the assay closer in line with the industry 
standard tests and would be more amenable to automation
[8,9].
 
Our results demonstrate proof of concept for the combination of multiplexed serodiagnosis of viral 
infection and blood-typing assays. However, blood typing requires identification of a larger range of 
surface antigens (such as the Rhesus group) and extensive pathogen testing also includes assays for 
syphilis and HBV. Further work will include the integration of these assays into the current 
microarray format
[11]
.  
In conclusion, we have successfully developed a proof of concept platform capable of blood typing 
human whole blood samples based on the ABO blood system, whilst at the same time testing the 
sample for the presence of antibodies specific for HIV/HCV. The major benefits of this system are its 
amenability to expansion with additional assays, i.e. rhesus typing or syphilis, HBV detection and also 
the ability to simultaneously test a number of samples on the same test slide, currently 16 but readily 
expandable to a 96-well format. 
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Tables 
 
Antigen (Ag) / 
antibody (Ab) 
Molecular Weight (Ag) / 
Class (Ab) 
Origin (Ag) 
/Target (Ab) 
Source 
HIV-1 gp41 (ARP 680) (Ag) 16 x 10
3
-28 x 10
3
 HIV NIBSC 
HIV-1 p24 His (EVA 673) 
(Ag) 
26 x 10
3
 HIV NIBSC 
HIV-2 env gp 36 (Ag) 34 x 10
3
 (+114 x 10
3
 β-Gal Fusion) HIV RDI 
HIV-2 env gp 36 (Ag) 32 x 10
3
 (+114 x 10
3
 β-Gal Fusion) HIV Virogen 
HCV Core (Ag) 36 x 10
3
 HCV Virostat 
HCV NS3 Fusion (Ag) 1 x 10
6
 HCV Virostat 
HCV NS4 (Ag) 19 x 10
3
 (+114 x 10
3
 β-Gal Fusion) HCV RDI 
LA2 (Ab) IgM A antigen Alba 
LB2 (Ab) IgM B antigen Alba 
 
Table 1. HIV/HCV pathogen specific antigens and blood typing antibodies utilised on the protein 
microarray. 
 
Antibody Target Subtype Source 
anti-HCV Core Mouse IgG1 Virogen 
anti-HCV NS3 Mouse IgG1 Virogen 
anti-HCV NS4 Mouse IgG2a RDI 
anti-HIV-1 p24 Mouse IgG1 Virogen 
anti-HIV-1 gp41 Mouse IgG1 RDI 
anti-HIV-2 gp36 Mouse IgG2a Virogen 
 
Table 2. Monoclonal antibodies used in the preparation of the mock antibody-positive plasma samples 
(HIV/HCV). 
 
 
Table 3. Thresholds derived from ROC curve analysis within which a blood sample can be defined as 
belonging to a particular ABO blood type group[12]. Threshold values are based upon an index score 
(ratio) of the A and B blood type antibody responses (LA2/LB2). 
  
ABO Blood Type Threshold Value of Index Score 
A ≥ 2.585 
B ≤ 0.612 
O 0.929 – 2.58 
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Figures 
 
 
Figure 1. Dose response curve demonstrating optimum conditions for mock antibody-positive plasma 
antibodies with the four best performing HIV/HCV antigens. HIV/HCV combined mock infected 
plasma at a 1/30 dilution.  
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Figure 2. Blood typing results for human mock antibody-positive ‘whole blood’ samples. HIV/HCV 
mock antibody-positive plasma at a 1/30 dilution with erythrocytes of type A or O blood type both in 
the presence and absence of monoclonal antibodies (MAbs) against HIV/HCV antigens. Mean relative 
signal value was calculated by dividing the mean signal/background value for each sample by the 
mean signal/background value obtained with a plasma only reference sample. Blank sample value is 
calculated based on the median response from 14 blank, non-spotted array locations. Error bars 
display standard error based on the ratio of the relative standard deviation (RSD) of the mock 
antibody-positive signal (a) and of the plasma only signal (b) respectively, i.e. √((RSDa)2 + (RSDb)2). 
          = Type A erythrocytes only,          = Type A erythrocytes + MAbs,          = Type O erythrocytes 
only,          = Type O erythrocytes + MAbs. 
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Figure 3. Serodiagnosis of pathogen infection analysis from mock antibody-positive human ‘whole 
blood’ samples. HIV/HCV mock antibody-positive plasma at a 1/30 dilution in the presence of 
monoclonal antibodies ((MAbs) at a concentration of 6 x 10
-10
 M) against HIV/HCV antigens. The 
mean relative signal value was calculated by dividing the mean signal/background value for each 
sample by the mean signal/background value obtained with a plasma only reference sample. The 
blank sample value is calculated based on the median response from 14 blank, non-spotted array 
locations. Mouse IgG antibody serves as a positive control. Error bars display the standard error based 
on the ratio of the relative standard deviation (RSD) of the mock antibody-positive signal (a) and of 
the plasma only signal (b) respectively, i.e. √((RSDa)2 + (RSDb)2). 
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